Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 4 | 2020 | 532 | 1.450 |
Why?
|
| Bayes Theorem | 2 | 2018 | 125 | 0.780 |
Why?
|
| Nose | 1 | 2020 | 42 | 0.760 |
Why?
|
| Search Engine | 1 | 2020 | 8 | 0.750 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 11 | 0.740 |
Why?
|
| Warts | 1 | 2020 | 23 | 0.740 |
Why?
|
| Mohs Surgery | 1 | 2019 | 10 | 0.730 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2019 | 17 | 0.720 |
Why?
|
| Seasons | 1 | 2020 | 98 | 0.720 |
Why?
|
| Correspondence as Topic | 1 | 2018 | 3 | 0.680 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 645 | 0.670 |
Why?
|
| Biopolymers | 1 | 2018 | 14 | 0.670 |
Why?
|
| Penile Erection | 1 | 2018 | 23 | 0.670 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2018 | 6 | 0.660 |
Why?
|
| Sutures | 1 | 2018 | 45 | 0.660 |
Why?
|
| Writing | 1 | 2018 | 42 | 0.650 |
Why?
|
| Niacinamide | 1 | 2018 | 25 | 0.650 |
Why?
|
| Epidemiologic Studies | 1 | 2018 | 30 | 0.650 |
Why?
|
| Skull Base Neoplasms | 1 | 2018 | 23 | 0.650 |
Why?
|
| Renal Veins | 1 | 2018 | 17 | 0.650 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 125 | 0.630 |
Why?
|
| Penis | 1 | 2018 | 84 | 0.630 |
Why?
|
| Scalp | 1 | 2018 | 53 | 0.630 |
Why?
|
| Probability | 1 | 2018 | 177 | 0.630 |
Why?
|
| Carcinoma, Papillary | 1 | 2018 | 65 | 0.630 |
Why?
|
| Decision Making | 1 | 2020 | 286 | 0.610 |
Why?
|
| Students | 1 | 2018 | 209 | 0.570 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 162 | 0.550 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 336 | 0.490 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 428 | 0.480 |
Why?
|
| Humans | 17 | 2022 | 54391 | 0.350 |
Why?
|
| Fissure in Ano | 1 | 2022 | 3 | 0.220 |
Why?
|
| Incontinentia Pigmenti | 1 | 2022 | 5 | 0.210 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2022 | 12 | 0.210 |
Why?
|
| Exanthema | 1 | 2022 | 36 | 0.210 |
Why?
|
| Thigh | 1 | 2021 | 40 | 0.200 |
Why?
|
| Organ Transplantation | 1 | 2021 | 49 | 0.200 |
Why?
|
| Young Adult | 3 | 2019 | 4318 | 0.190 |
Why?
|
| Immunocompetence | 1 | 2020 | 19 | 0.190 |
Why?
|
| Male | 7 | 2020 | 27347 | 0.190 |
Why?
|
| Sunlight | 1 | 2019 | 9 | 0.180 |
Why?
|
| Washington | 1 | 2019 | 46 | 0.180 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 130 | 0.180 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2018 | 7 | 0.170 |
Why?
|
| Universities | 1 | 2019 | 164 | 0.170 |
Why?
|
| Dura Mater | 1 | 2018 | 11 | 0.170 |
Why?
|
| Nose Neoplasms | 1 | 2018 | 10 | 0.160 |
Why?
|
| History, 19th Century | 1 | 2018 | 34 | 0.160 |
Why?
|
| Whole Body Imaging | 1 | 2018 | 25 | 0.160 |
Why?
|
| Likelihood Functions | 1 | 2018 | 61 | 0.160 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2018 | 24 | 0.160 |
Why?
|
| Disclosure | 1 | 2018 | 39 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2018 | 41 | 0.160 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 35 | 0.160 |
Why?
|
| Problem Solving | 1 | 2018 | 46 | 0.160 |
Why?
|
| Organ Size | 1 | 2018 | 237 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2018 | 114 | 0.160 |
Why?
|
| Endocarditis | 1 | 2018 | 33 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2018 | 104 | 0.160 |
Why?
|
| Informed Consent | 1 | 2018 | 92 | 0.160 |
Why?
|
| Syndrome | 1 | 2018 | 253 | 0.150 |
Why?
|
| Thyroidectomy | 1 | 2018 | 103 | 0.150 |
Why?
|
| Sex Factors | 1 | 2019 | 766 | 0.150 |
Why?
|
| Aged | 3 | 2020 | 10060 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 385 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2018 | 141 | 0.140 |
Why?
|
| Communication | 1 | 2018 | 265 | 0.140 |
Why?
|
| Age Factors | 1 | 2019 | 1199 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2390 | 0.140 |
Why?
|
| Adult | 4 | 2020 | 14207 | 0.130 |
Why?
|
| Phenotype | 1 | 2018 | 819 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 3431 | 0.130 |
Why?
|
| Immunity | 1 | 2013 | 37 | 0.120 |
Why?
|
| Central Nervous System Depressants | 1 | 2013 | 78 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6459 | 0.110 |
Why?
|
| Anastomosis, Surgical | 1 | 2011 | 72 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2011 | 27 | 0.100 |
Why?
|
| Bronchi | 1 | 2011 | 51 | 0.100 |
Why?
|
| Suture Techniques | 1 | 2011 | 70 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1616 | 0.100 |
Why?
|
| Ethanol | 1 | 2013 | 323 | 0.100 |
Why?
|
| Female | 4 | 2020 | 28471 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2019 | 5612 | 0.090 |
Why?
|
| Middle Aged | 3 | 2020 | 13082 | 0.080 |
Why?
|
| Adolescent | 1 | 2019 | 6900 | 0.080 |
Why?
|
| Aging | 1 | 2013 | 784 | 0.080 |
Why?
|
| Child | 1 | 2019 | 7368 | 0.070 |
Why?
|
| Animals | 2 | 2018 | 14409 | 0.060 |
Why?
|
| Brain | 1 | 2013 | 1392 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2022 | 2923 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2011 | 1035 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2021 | 103 | 0.050 |
Why?
|
| Missouri | 1 | 2020 | 65 | 0.050 |
Why?
|
| Hand | 1 | 2020 | 58 | 0.050 |
Why?
|
| Middle East | 1 | 2018 | 8 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2020 | 720 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2013 | 37 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 145 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 80 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 79 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 206 | 0.030 |
Why?
|
| Cerebellum | 1 | 2013 | 142 | 0.030 |
Why?
|
| RNA | 1 | 2013 | 202 | 0.030 |
Why?
|
| Astrocytes | 1 | 2013 | 142 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2013 | 234 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 315 | 0.030 |
Why?
|
| Hippocampus | 1 | 2013 | 242 | 0.030 |
Why?
|
| Bronchial Diseases | 1 | 2011 | 8 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 435 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2011 | 51 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 232 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 354 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 165 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1090 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2011 | 161 | 0.020 |
Why?
|
| Survival Rate | 1 | 2011 | 954 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 991 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 2001 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1546 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 1362 | 0.020 |
Why?
|